Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Short Interest Update

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) was the target of a significant decline in short interest in the month of February. As of February 15th, there was short interest totalling 61,900 shares, a decline of 55.3% from the January 31st total of 138,500 shares. Based on an average trading volume of 4,630,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 3.4% of the company’s shares are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cyclerion Therapeutics stock. Renaissance Technologies LLC acquired a new stake in shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 10,611 shares of the company’s stock, valued at approximately $34,000. Renaissance Technologies LLC owned approximately 0.39% of Cyclerion Therapeutics as of its most recent filing with the Securities & Exchange Commission. 75.62% of the stock is owned by hedge funds and other institutional investors.

Cyclerion Therapeutics Stock Performance

CYCN stock opened at $2.67 on Friday. The company’s 50 day simple moving average is $3.19 and its 200-day simple moving average is $2.93. Cyclerion Therapeutics has a 52-week low of $1.27 and a 52-week high of $9.47.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.